Logo

Illumina to Buy Back as Much as $75M in Stock

Feb 27, 2007
NEW YORK (GenomeWeb News) — Illumina plans to buy back as much as $75 million of its outstanding common stock over a six-month period, and has filed a trading plan to allow it to complete the transactions.
 
Earlier this month Illumina said it would use $200 million from a senior note sale to buy back its own stock.
Breaking News
The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.